In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...

Vertex Pharmaceuticals stock (NASDAQ NDAQ: VRTX) has seen a 33% rise this year, significantly outperforming the broader S&P500 index, down 23%. Even if we look at the longer term, VRTX stock, with ...

VRTX currently has a PEG ratio of 87.91. Another notable valuation metric for BMY is its P/B ratio of 5.75. The P/B ratio pits a stock's market value against its book value, which is defined as ...